RecruitingPHASE2, PHASE3NCT04047576
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
Studying IgG4-related retroperitoneal fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University International Hospital
- Principal Investigator
- Hui Gao, DoctorPeking University International Hospital
- Intervention
- Sirolimus(drug)
- Enrollment
- 60 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (1)
- Peking University International Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04047576 on ClinicalTrials.govOther trials for IgG4-related retroperitoneal fibrosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT06741423Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via RadiomicsHeidelberg University
- RECRUITINGPHASE4NCT05428826Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal FibrosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT04314323National Registry of IRPF in ChinaPeking Union Medical College Hospital
- RECRUITINGNCT04312854A Prospective Cohort Study of IRPF in ChinaPeking Union Medical College Hospital